The patented technology provides diagnostic and treatment capabilities that use a unified code that is intrinsic to physiological brain function. This approach can be used for the treatment of disorders and supplements existing diagnostic and treatment methods with quantitative data analysis. Examples of disorders that potentially may be treated using the patented methods may include Alzheimer’s disease, Parkinson’s disease, and Post-Traumatic Stress.
The methods are achieved by the unification of cognitive and neural phenomena known as the Fundamental Code Unit (FCU), representing identifiable patterns of brain activity at the sub-molecular, molecular, and cellular levels (intra-brain communications), as well as their manifestations in thought and language (inter-brain communications). The Medical Co-Processor (MCP) device receives input from living tissue through at least one read modality; determines at least one identifiable pattern of tissue activity at a sub-molecular, molecular, or cellular level, where the pattern of tissue activity indicates a defective tissue function. The device computes a signal to effect alterations to the living tissue so as to correct the defective tissue function based on the determined pattern and delivers the signal to the living tissue through at least one write modality.
Some of the read modalities use highly technological techniques, such as MRI imaging or EEG analysis, while other read modalities use more accessible techniques, such as linguistic analysis, audiovisual stimulation, or motion tracking/gait analysis. Some of the writing modalities use light or specific molecules to stimulate or inhibit the activation of a group of neurons and the release of some chemicals in patients suffering from a neurological disease.
Thus, the patented technology provides great potential for the diagnosis and treatment of a variety of neurological disorders. Further, the patented technology may form the basis of additional advances, such as bridging the structural gap between “artificial” and “real” intelligence, new data storage methodologies, and other uses of the ability to “read” FCU information from the human brain and “write” FCU information to the human brain.
For more information on this topic, contact your Intellectual Property counsel at Smith, Gambrell & Russell, LLP.